We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ROIV market cap is 8.85B. The company's latest EPS is USD 5.3967 and P/E is 2.01.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 27.38M | 21.62M | 37.1M | 37.14M | 28.93M |
| Operating Income | -234.17M | -276.41M | -276.45M | -287.53M | -266M |
| Net Income | -33.62M | -291.82M | -304.33M | 5.1B | -151.12M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 67.69M | 23.8M | 55.29M | 61.28M | 124.8M |
| Operating Income | -553.81M | -1.07B | -1.35B | -1.18B | -1.11B |
| Net Income | 1.2B | -809.23M | -845.26M | -1.01B | 4.35B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.39B | 2.14B | 2.07B | 7.31B | 7.22B |
| Total Liabilities | 782.02M | 802.51M | 739.91M | 728.1M | 773.95M |
| Total Equity | 1.61B | 1.33B | 1.33B | 6.58B | 6.45B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.48B | 2.59B | 2.59B | 2.39B | 7.22B |
| Total Liabilities | 368.36M | 527.69M | 523.7M | 782.02M | 773.95M |
| Total Equity | 2.09B | 2.04B | 2.04B | 1.61B | 6.45B |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -843.39M | -249.93M | -446.36M | -656.81M | -765.27M |
| Investing | -44.27M | 105k | -36.35M | 5.2B | 5.2B |
| Financing | 499.46M | 7.48M | 221.35M | 451.99M | 419.36M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -758.75M | -552.14M | -677.73M | -843.39M | -765.27M |
| Investing | 1.69B | -31.7M | 303.3M | -44.27M | 5.2B |
| Financing | 214.08M | 456.26M | 306.79M | 499.46M | 419.36M |
| Market Cap | 8.85B |
| Price to Earnings Ratio | 2.01 |
| Price to Sales Ratio | 70.05 |
| Price to Cash Ratio | 1.34 |
| Price to Book Ratio | 1.36 |
| Dividend Yield | - |
| Shares Outstanding | 805.85M |
| Average Volume (1 week) | 3.3M |
| Average Volume (1 Month) | 4.94M |
| 52 Week Change | 15.41% |
| 52 Week High | 13.24 |
| 52 Week Low | 8.245 |
| Spread (Intraday) | 0.68 (6.18%) |
| Company Name | Roivant Sciences Ltd |
| Address |
clarendon house hamilton D0 HM11 |
| Website | https://www.roivant.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
